Haldol

(Haloperidol Decanoate)

ApprovedSmall molecule

WWim Janssens

Haldol is one of 129 small molecule programs targeting Schizoaffective Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

128

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Schizoaffective DisorderActive, not recruiting

DeliriumCompleted

SchizophreniaTerminated

Advanced CancersActive, not recruiting

TIPSCompleted

Schizoaffective DisorderPreclinical

Active, not recruiting

DeliriumApproved

Completed

SchizophreniaApproved

Terminated

Advanced CancersPhase 2

Active, not recruiting

TIPSPreclinical

Completed

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Haldol

WWim Janssens

Approved

2 2

Inapsine

Jazz Pharmaceuticals

Preclinical

1 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Depakote

Ibrance

Lunesta

3 8

Rapamune

PPrism Pharmaceuticals

Preclinical

1 9

Persantine

Boehringer Ingelheim

Preclinical

1 10

Luvox

SSolvay Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Advanced Cancers

NCT01949662

Clinical

Trials by Indication[1]

Schizophrenia2 trials

A Comparison of Long-acting Injectable Medications for Schizophrenia

Completed·NNew York State Psychiatric Institute·Phase 4·NCT01136772·311 enrolled

Lamictal TM, Haloperidol Decanoate in Schizophrenia

Terminated·CCentral Mental Clinic for Outpatients of Baku City·Phase 4·NCT00947375·335 enrolled

Tic Disorder1 trial

Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

Completed·—·Phase 3·NCT04327843·22 enrolled

Delirium1 trial

Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol

Completed·—·Phase 4·NCT01174290·68 enrolled

TIPS1 trial

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

Completed·UUniversity Hospitals Cleveland Medical Center·N/A·NCT01152697·30 enrolled

Schizoaffective Disorder1 trial

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

Completed·UUS Department of Veterans Affairs·N/A·NCT00018642

1 more indication

Advanced Cancers1 trial

A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01949662·93 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 14, 1986

HALDOL

NDA NDA018701

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Haloperidol Decanoate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Haloperidol Decanoate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Haloperidol Decanoate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018701). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wim Janssens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWim Janssens

Haldol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Schizophrenia2 trials

Tic Disorder1 trial

Delirium1 trial

TIPS1 trial

Schizoaffective Disorder1 trial

Advanced Cancers1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News